11 Jul , 2024 By : Debdeep Gupta
Shares of Zydus Lifesciences touched a 52-week high of Rs 1,203.20 in the early trade on July 11, riding on the final approval from the United States Food and Drug Administration (USFDA) to market a key drug used to treat chronic heart failure.
At 09:21 am, Zydus Lifesciences was quoting at Rs 1,178.95, down Rs 1.45, or 0.12 percent, on the BSE.
Sacubitril and Valsartan Tablets (24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg) are combinations used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization.
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
The group now has 399 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.
Also, the company received tentative approval from the USFDA to market Diroximel Fumarate Delayed-Release Capsules, 231 mg.
Earlier this month, the company received tentative approval from the USFDA to market Azilsartan Medoxomil Tablets, 40 mg, and 80 mg.
0 Comment